Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

A2, Synlait shares climb as takeover bid revives optimism

A2, Synlait shares climb as takeover bid revives optimism about Chinese appetite for milk


By Paul McBeth

Sept. 16 (BusinessDesk) - A2 Milk and Synlait Milk shares jumped in early trading as a A$1.5 billion takeover bid for Bellamy's Australia revived optimism that Chinese demand for dairy products remains strong.

ASX-listed Bellamy's today said it's received a A$13.25 per share offer from China Mengniu Dairy Co and that its board will support the bid. That's a premium to the A$8.32 price the shares closed at on Friday. China Mengniu is familiar with the Australasian market through Yashili New Zealand and Burra Foods Australia. It was also one of the unsuccessful suitors of Murray Goulburn. Bellamy's soared 51 percent to A$12.55, less than the A$12.65 cash component of the offer which also allows for a 60 cent special dividend.

A2 has had more success than its smaller Tasmanian rival in navigating the Chinese market, especially in securing regulatory approvals. A2's shares rose as high as $15.40 in early trading today, and were recently up 4.6 percent at $14.67 after the ASX opened. Supplier Synlait was recently up 3.3 percent at $9.30, having climbed as high as $9.51.

"I think it’s probably a response to the fact that A2 is arguably better positioned than Bellamy’s in China, given the issues that the latter has encountered with securing regulatory approvals," said Fat Prophets head of research Greg Smith.

"The takeover offer is also a reminder that the demand growth story in China here is very real, and reaffirmed by the bid from a Chinese company."

Tasmanian-based Bellamy's ran into trouble in China in 2016 when that country tightened its infant formula regulation. It subsequently had to raise money at a discount to change its milk supply contract with Fonterra Cooperative Group to meet China's tougher import criteria.

Meanwhile, A2 recently reported a 74 percent jump in revenue from China and Asia at $405.7 million for the year ended June.

A number of Chinese firms have been willing to pay above the odds for New Zealand and Australian dairy companies. Locally, Westland Dairy Cooperative was sold to Inner Mongolia Yili Industrial Group for $588 million, a premium of almost 150 percent.

Smith said to expect more interest from Chinese suitors.

"The first move is rarely the last, and other Australasian listed companies could also be in the frame of M&A interest from Chinese predators," he said.

(BusinessDesk)

ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Marine And Freshwater Reports: EDS Calls For Urgent Action On Marine Management

“There are some big issues to address. These include many marine species and habitats that are in serious trouble. Of the sample investigated, the report finds that 22% of marine mammals, 90% of seabirds and 80% of shorebirds are threatened with or actually at risk of extinction..." More>>

ALSO:

$7.5 Billion Surplus: Government Accounts "Show Strong Economy"

“The surplus and low levels of debt show the economy is in good shape. This allows the Government to spend more on infrastructure and make record investments in health and education,” Grant Robertson says. More>>

ALSO:

New OIO Application Trumps Judicial Review: OceanaGold Cleared To Buy Land For Waihi Tailings Expansion

In a surprise turnaround, the government has given OceanaGold a greenlight to buy land to expand its Waihi mine after the application was previously turned down by Land Information Minister Eugenie Sage. More>>

ALSO:

Christchurch Rebuild: Fletcher Sued For $7.5m Over Justice Precinct

Fletcher Building is being sued for $7.5 million by utilities contractor Electrix, one of the subcontractors on the Christchurch Justice and Emergency Services Precinct. More>>

Three New Drugs: PHARMAC Signs Bundle Deal For More Cancer Medicines

420 New Zealanders with lung cancer, breast cancer, multiple sclerosis and respiratory disease will benefit each year from a bundle deal PHARMAC has finalised with a medicine supplier. More>>

ALSO: